Received by email:

File: PR.June.13.2017.Pres.T.Final.docx

/


CSE: MDM          FSE: 2M0     OTCQB: MRPHF
 

News Release    June 13, 2017, Kelowna, BC

Marapharm Ventures Inc. "Marapharm" announces the appointment of President of Operations

The Marapharm Board of Directors has appointed Brian Lovig as Interim-President while the Company expands its operatio
--->ns and prepares to scale production in Nevada.

Brian Lovig is a businessman with vast entrepreneurial experience who has been involved in the establishment of multip
--->le businesses in multiple sectors. He is the founder and facilitator of Marapharm and from time to time has been a con
--->sultant to Marapharm and is familiar with its current projects and personnel. 
 
"Marapharm recently was issued Medical Marijuana Licenses for 290,000 square feet of cultivation and production in the
---> state of Nevada. It is expected that these will transition to recreational licenses. Marapharm is growing rapidly in 
--->other states also and has asked for my help with operations, so I've agreed to a 6 month work plan. I have arranged fo
--->r others to manage most of my other businesses so that I am able to focus on Marapharm. I've consulted for Marapharm a
--->nd have brought opportunities to Marapharm in the past which have had a lot of value added by the Marapharm team for s
--->hareholders. I'm looking forward to doing some big things during the short time that I will be at the helm." Brian Lov
--->ig, Marapharm President.  
 
ABOUT MARAPHARM VENTURES INC.
www.marapharm.com 

Marapharm has more than 300,000 square feet of medical marijuana licenses for its land and facilities in WA, CA and NV
--->. In Nevada, the building footprint is 360,000 square feet. The Nevada Department of Agriculture report by Tessa Rogni
--->er states that the average size of a cultivation facility in Nevada is 26,000 square feet. About three years ago, Mara
--->pharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary securi
--->ty clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contac
--->ted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR. Marapharm owns 15 mil
--->lion shares and warrants of Veritas Pharma Inc., a public company.
Additional information on the operations or financial results of Marapharm are included in reports on file with applic
--->able securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (
--->www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION: 
www.marapharm.com  or 778-583-4476 email info@marapharm.com

STOCK EXCHANGES:
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in E
--->urope, ticker symbol 2M0 on the FSE.

Neither the CSE, the FSE nor the OTCQBtrademark has approved nor disapproved the contents of this press release. Neith
--->er the CSE, the FSE nor the OTCQBtrademark accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "
--->anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions 
--->are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties a
--->nd other factors that may cause actual results or events to differ materially from those anticipated in such forward-l
--->ooking statements are based on reasonable assumption but no assurance can be given that these expectations will prove 
--->to be correct and the forward-looking statements included in this news release should not be unduly relied upon.